Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Testing effectiveness (Phase 2)Study completedNCT01785992
What this trial is testing

The Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Imperial College London 27
Not applicableLooking for participantsNCT06925984
What this trial is testing

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

Who this might be right for
OligoProgressive Metastatic Disease
Jules Bordet Institute 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT06125522
What this trial is testing

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Who this might be right for
Breast Cancer
Pfizer 11
Testing effectiveness (Phase 2)Ended earlyNCT03070002
What this trial is testing

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Who this might be right for
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more
Northwestern University 1
Not applicableStudy completedNCT06607601
What this trial is testing

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

Who this might be right for
Metastatic Breast Cancer
Aetion, Inc. 724
Early research (Phase 1)Study completedNCT03471663
What this trial is testing

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 200
Testing effectiveness (Phase 2)Looking for participantsNCT05716516
What this trial is testing

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

Who this might be right for
Metastatic Breast Cancer
Dartmouth-Hitchcock Medical Center 36
Testing effectiveness (Phase 2)Study completedNCT01869192
What this trial is testing

Phase II Trial for Large ER-Negative Breast Cancers

Who this might be right for
Malignant Neoplasm of Female Breast
University of Colorado, Denver 72
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Large-scale testing (Phase 3)Ended earlyNCT00684216
What this trial is testing

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 10
Testing effectiveness (Phase 2)Study completedNCT03065621
What this trial is testing

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)

Who this might be right for
Breast Cancer Female
Jules Bordet Institute 100
Large-scale testing (Phase 3)Active Not RecruitingNCT06680921
What this trial is testing

SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 482
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Large-scale testing (Phase 3)Active Not RecruitingNCT04546009
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 992
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Large-scale testing (Phase 3)Study completedNCT04109066
What this trial is testing

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 521
Testing effectiveness (Phase 2)Study completedNCT02598557
What this trial is testing

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Who this might be right for
Stage 0 Breast Cancer AJCC v6 and v7Stage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
National Cancer Institute (NCI) 180
Testing effectiveness (Phase 2)Ended earlyNCT00303615
What this trial is testing

Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Legacy Health System 5
Next Page